

Supplementary Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by race/ethnicity† -- National Immunization Survey–Teen (NIS-Teen), United States, 2016.

Vaccines	Race/Ethnicity					
	White only, non-Hispanic (n=12,883)	Black only, non-Hispanic (n=1,990)	Hispanic (n=3,223)	American Indian/Alaska Native only, non-Hispanic (n=300)	Asian, non-Hispanic (n=862)	Multiracial, non-Hispanic (n=1,127)
	% (95% CI)§	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Tdap[¶]≥1 dose	89.3 (±0.9)	89.6 (±2.0)	85.4 (±2.6)**	89.7 (±5.2)	83.7 (±7.2)	86.2 (±4.6)
MenACWY^{††} ≥1 dose	81.2 (±1.2)	85.5 (±2.2)**	83.8 (±2.7)	78.4 (±7.3)	82.7 (±6.8)	76.8 (±4.8)
MenACWY ≥2 doses (age 17 years only)	38.7 (±3.3)	44.6 (±9.0)	37.0 (±8.3)	NA	44.6 (±12.3)	36.8 (±12.4)
HPV^{§§}vaccine coverage by doses						
All Adolescents						
≥ 1 dose	54.7 (±1.4)	65.9 (±3.3)**	69.8 (±3.1)**	62.3 (±9.5)	62.5 (±6.6)**	60.7 (±5.4)**
≥ 2 doses	45.2 (±1.5)	51.6 (±3.5)**	56.8 (±3.5)**	46.6 (±9.3)	51.7 (±6.7)	47.5 (±5.4)
≥ 3 doses	34.8 (±1.4)	37.0 (±3.4)	41.5 (±3.5)**	32.4 (±8.6)	44.4 (±6.7)**	36.8 (±5.1)
HPV UTD ^{¶¶}	39.6 (±1.4)	46.0 (±3.5)**	49.9 (±3.5)**	42.5 (±9.1)	47.2 (±6.7)**	42.2 (±5.3)
FEMALES						
≥ 1 dose	60.0 (±2.0)	70.0 (±4.9)**	71.8 (±4.5)**	68.3 (±12.2)	71.9 (±7.0)**	65.1 (±6.7)
≥ 2 doses	51.1 (±2.1)	56.0 (±5.2)	61.2 (±5.1)**	57.1 (±13.2)	62.6 (±8.1)**	56.4 (±6.8)
≥ 3 doses	40.4 (±2.1)	43.3 (±5.2)	45.9 (±5.2)	46.9 (±13.4)	55.0 (±8.9)**	44.3 (±6.8)
HPV UTD	45.7 (±2.1)	51.2 (±5.2)	55.3 (±5.3)**	54.1 (±13.2)	58.2 (±8.6)**	49.6 (±6.8)
MALES						
≥ 1 dose	49.7 (±2.0)	61.4 (±4.4)**	67.8 (±4.1)**	56.0 (±13.8)	53.5 (±9.8)	56.6 (±8.4)
≥ 2 doses	39.7 (±2.0)	46.8 (±4.5)**	52.5 (±4.7)**	35.6 (±11.3)	41.2 (±8.9)	39.5 (±7.8)
≥ 3 doses	29.6 (±1.8)	30.1 (±4.0)	37.2 (±4.6)**	17.0 (±7.0)**	34.3 (±8.4)	30.0 (±7.1)
HPV UTD	34.0 (±1.9)	40.5 (±4.4)**	44.6 (±4.7)**	30.3 (±10.3)	36.6 (±8.6)	35.4 (±7.6)
≥2 MMR vaccine doses	91.8 (±0.8)	91.6 (±1.7)	88.9 (±1.9)**	90.5 (±5.7)	90.3 (±5.8)	89.1 (±4.4)
≥3 Hepatitis B	92.4 (±0.8)	92.3 (±1.6)	89.2 (±1.9)**	94.4 (±4.0)	88.4 (±6.1)	90.8 (±3.3)
Varicella						
History of varicella***	15.7 (±1.1)	11.2 (±2.1)	15.9 (±2.4)	19.6 (±6.9)	15.5 (±4.3)	15.5 (±3.8)
Among adolescents with no history of varicella:						
≥1 dose vaccine	95.5 (±0.6)	96.1 (±1.2)	93.0 (±2.2)**	93.9 (±6.1)	94.0 (±6.6)	96.3 (±1.7)
≥2 doses vaccine	86.1 (±1.1)	87.0 (±2.7)	84.2 (±2.8)	79.5 (±8.9)	84.4 (±7.2)	84.8 (±4.3)

History of varicella or received ≥2 doses varicella vaccine	88.3 (±0.9)	88.5 (±2.4)	86.7 (±2.4)	83.5 (±7.3)	86.8 (±6.2)	87.2 (±3.7)
--	-------------	-------------	-------------	-------------	-------------	-------------

Abbreviations: CI = confidence interval; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; HPV = human papillomavirus; MMR = measles, mumps, and rubella; NA = not available (estimate not reported because unweighted sample size for the denominator was <30 or (95%CI half width / estimate) > 0.6)

* Adolescents (N=20,475) in the 2016 NIS-Teen were born January 1998 through February 2004.

† Adolescent’s race/ethnicity was reported by their parent or guardian. Adolescents identified in this report as white, black, Asian, American Indian/Alaska Native, or multiracial were reported by the parent or guardian as non-Hispanic. Adolescents identified as multiracial had more than one race category selected. Adolescents identified as Hispanic might be of any race. Native Hawaiian or other Pacific Islanders were not included in the table because of small sample sizes (n=90).

§ The number inside the parentheses is the product of 1.96 and the estimated standard error for the point estimate. The 95% confidence interval can be constructed by adding to or subtracting the number from the point estimate. Estimates with 95% CI half-widths >10 might not be reliable.

¶ Includes percentages receiving Tdap vaccine at or after age 10 years.

** Statistically significant difference (p<0.05) in estimated vaccination coverage by race/ethnicity; referent group was white, non-Hispanic adolescents.

†† Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.

§§ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). For ≥1, ≥2, and ≥3 dose measures, percentages are reported among females and males combined (N = 20,475) and for females only (N = 9,661) and males only (N =10,814).

¶¶ HPV UTD - Includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose.

***By parent/guardian report or provider records.

Supplementary Table 2. Distribution of Vaccine Providers for adolescents aged 13–17 years by MSA* and provider facility type† -- National Immunization Survey–Teen (NIS-Teen), United States, 2016

	Total		ALL PUBLIC FACILITIES		ALL HOSPITAL FACILITIES		ALL PRIVATE FACILITIES		ALL SCHOOL/OTHER		MIXED		ALL MILITARY FACILITIES / ALL WIC CLINIC FACILITIES / ALL PHARMACIES	
	N	% (95%. C.I.)	N	% (95%. C.I.)	N	% (95%. C.I.)	N	% (95%. C.I.)	N	% (95%. C.I.)	N	% (95%. C.I.)	N	% (95%. C.I.)
Total	20,475	100	2,925	14.5 (13.6-15.5)	2,426	10.1 (9.4-10.9)	10,146	53.0 (51.7-54.3)	328	2.0 (1.6-2.5)	4,209	19.0 (18.1-20.0)	289	1.3 (1.1-1.6)
MSA, Central City	7,979	40.1 (38.9-41.4)	936	14.4 (12.8-16.0)	1,064	11.6 (10.3-13.0)	4,196	52.9 (50.7-55.0)	139	2.1 (1.5-3.1)	1,437	17.7 (16.1-19.4)	140	1.4 (1.0-1.9)
MSA, Non-Central City	8,248	46.9 (45.6-48.1)	740	10.3 (9.1-11.6)	849	9.0 (8.0-10.1)	4,883	60.2 (58.4-62.1)	113	1.8 (1.2-2.5)	1,496	17.3 (16.0-18.8)	125	1.4 (1.0-1.9)
Non-MSA	4,248	13.0 (12.4-13.6)	1,249	30.4 (28.1-32.9)	513	9.9 (8.5-11.6)	1,067	27.3 (25.0-29.7)	76	2.2 (1.3-3.5)	1,276	29.5 (27.2-31.9)	NA	(.-.)

Abbreviations: CI = confidence interval; WIC = Women, Infants, and Children; NA = not available (estimate not reported because unweighted sample size for the denominator was <30 or (95%CI half width / estimate) > 0.6)

* MSA status was determined based on household-reported county of residence, and was grouped into three categories: MSA central city, MSA non-central city, and non-MSA. MSA and central city were as defined by the U.S. Census Bureau (https://www.census.gov/geo/reference/gtc/gtc_cbsa.html). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.

† Self-reported by provider. All public facilities includes public health clinics, community health centers, rural health clinics and migrant health centers. All hospital facilities include hospital-based clinics, university clinics, and residency teaching practices. All private facilities includes private clinics, HMOs and group practices. All school/other provider includes school-based health centers and unknown responses. Mixed provider includes more than one type of provider. All military facilities / all WIC clinic facilities/ all pharmacies include military health facilities for the Army, Navy, Air Force, Marines, and Coast Guards, facilities receiving federal funds through the Women, Infant, and Children program, and all pharmacies. Facility type is missing for n=152 respondents.

Supplementary Table 3. Estimated vaccination coverage with ≥1 HPV vaccine* among adolescents aged 13–17 years by HHS Region, state, selected local area, and territory -- National Immunization Survey–Teen (NIS-Teen), United States, 2013 - 2016.

	NIS-TEEN 2013 (n=18,264)	NIS-TEEN 2014 (n=20,827)	NIS-TEEN 2015 (n=21,875)	NIS-TEEN 2016 (n=20,475)	MOST CURRENT 4 YEARS ANNUAL AVERAGE INCREASE†
	% (95% CI)§	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
United States Overall	45.7 (44.3-47.1)	50.6 (49.3-52.0)	56.1 (54.9-57.4)	60.4 (59.2-61.6)	5.0 (4.3-5.6)
Region I	56.5 (53.2-59.7)	60.8 (57.4-64.1)	69.3 (65.9-72.5)	69.9 (66.7-72.9)	4.8 (0.4-9.2)
Connecticut	54.1 (47.5-60.5)	56.7 (50.3-62.9)	68.0 (62.1-73.4)	62.2 (55.8-68.2)	3.6 (-6.9-14.1)
Maine	51.0 (44.8-57.1)	59.8 (53.5-65.8)	65.9 (59.9-71.4)	70.0 (63.9-75.4)	6.3 (3.1-9.5)
Massachusetts	57.4 (51.5-63.2)	61.5 (55.3-67.4)	68.1 (61.6-74.0)	71.4 (65.7-76.5)	4.8 (3.1-6.5)
New Hampshire	54.3 (48.2-60.3)	63.3 (57.8-68.5)	71.9 (65.7-77.4)	69.9 (63.7-75.5)	5.5 (-2.7-13.6)
Rhode Island	72.9 (66.6-78.3)	72.4 (66.7-77.4)	84.2 (79.9-87.7)	88.9 (84.7-92.1)	6.2 (0.0-12.4)
Vermont	50.5 (44.0-56.9)	56.8 (50.2-63.1)	67.4 (61.6-72.6)	70.3 (64.6-75.5)	6.9 (2.3-11.5)
Region II	46.3 (42.6-50.1)	50.1 (46.0-54.1)	60.8 (57.1-64.3)	67.2 (63.8-70.5)	7.3 (3.8-10.8)
New Jersey	39.0 (32.5-45.8)	41.6 (34.9-48.6)	59.7 (53.5-65.6)	58.5 (52.4-64.3)	7.6 (-3.5-18.6)
New York	49.9 (45.4-54.4)	54.2 (49.2-59.2)	61.3 (56.8-65.6)	71.5 (67.3-75.4)	7.2 (3.4-11.1)
NY-City of New York	55.1 (48.3-61.7)	57.3 (50.1-64.1)	68.9 (62.9-74.3)	76.8 (70.8-81.9)	7.7 (2.7-12.7)
NY-Rest of State	46.6 (40.7-52.7)	52.3 (45.4-59.1)	56.4 (50.1-62.4)	68.1 (62.3-73.5)	6.9 (2.1-11.8)
Region III	45.6 (41.9-49.3)	53.3 (49.8-56.7)	57.0 (53.5-60.3)	61.2 (57.9-64.4)	5.0 (2.3-7.7)
Delaware	52.6 (46.3-58.9)	61.0 (54.2-67.4)	65.2 (59.4-70.7)	70.7 (64.9-75.8)	5.8 (3.5-8.2)
Dist. of Columbia	61.7 (51.1-71.3)	71.7 (64.6-77.8)	74.7 (68.9-79.8)	79.2 (73.5-84.0)	4.9 (0.7-9.1)
Maryland	42.0 (34.5-49.8)	52.3 (45.3-59.1)	60.3 (53.7-66.7)	64.5 (58.1-70.5)	7.4 (3.1-11.6)
Pennsylvania	51.6 (46.0-57.2)	56.9 (51.2-62.3)	59.0 (53.7-64.1)	64.4 (59.3-69.2)	4.1 (2.1-6.0)
PA-Philadelphia	67.2 (60.5-73.2)	71.5 (64.9-77.3)	79.4 (74.0-83.9)	80.7 (75.4-85.0)	4.7 (0.6-8.8)
PA-Rest of State	49.6 (43.4-55.9)	55.0 (48.7-61.1)	56.3 (50.4-62.0)	62.3 (56.6-67.6)	4.0 (1.3-6.7)
Virginia	38.8 (30.8-47.6)	47.5 (40.1-55.1)	50.4 (42.5-58.3)	53.6 (46.0-61.0)	4.6 (0.4-8.8)
West Virginia	39.4 (33.3-45.8)	50.2 (43.7-56.6)	53.5 (47.4-59.5)	54.2 (47.5-60.8)	4.9 (-2.2-12.0)
Region IV	40.4 (37.6-43.3)	47.3 (44.5-50.1)	51.4 (48.6-54.1)	55.8 (53.1-58.5)	5.0 (3.1-6.9)
Alabama	36.2 (30.3-42.5)	40.9 (35.0-47.1)	48.4 (42.1-54.7)	51.7 (45.3-58.0)	5.4 (3.1-7.7)
Florida	38.5 (31.9-45.5)	48.9 (41.7-56.2)	53.7 (46.7-60.6)	55.9 (49.2-62.5)	5.7 (0.2-11.2)
Georgia	46.9 (39.2-54.8)	53.0 (46.3-59.6)	52.6 (46.3-58.9)	67.3 (60.9-73.2)	6.3 (-3.2-15.9)

Kentucky	32.9 (26.8-39.6)	37.6 (31.3-44.3)	45.8 (39.7-52.0)	48.0 (41.7-54.4)	5.4 (1.9-8.8)
Mississippi	32.9 (26.7-39.7)	35.9 (29.9-42.4)	45.5 (39.5-51.5)	45.6 (39.4-52.0)	4.8 (-0.7-10.3)
North Carolina	46.0 (39.4-52.7)	57.9 (51.5-64.0)	56.7 (50.5-62.7)	57.5 (51.0-63.8)	3.2 (-5.8-12.2)
South Carolina	40.9 (33.8-48.3)	40.5 (34.2-47.2)	44.2 (38.1-50.5)	44.2 (37.4-51.3)	1.4 (-1.2-4.0)
Tennessee	38.6 (32.5-45.2)	38.9 (32.6-45.6)	48.7 (42.3-55.1)	55.3 (48.5-61.9)	5.9 (0.1-11.8)
Region V	42.5 (39.9-45.2)	50.5 (48.0-53.1)	54.4 (51.8-56.9)	58.4 (55.8-61.0)	5.2 (2.1-8.2)
Illinois	43.8 (38.5-49.3)	54.3 (49.5-59.0)	53.0 (48.5-57.4)	63.5 (58.6-68.1)	5.6 (-2.1-13.4)
IL-City of Chicago	55.9 (47.2-64.2)	71.4 (64.5-77.5)	69.4 (63.0-75.1)	73.1 (63.2-81.2)	4.5 (-8.0-17.0)
IL-Rest of State	41.0 (34.8-47.5)	50.4 (44.8-56.0)	49.4 (44.2-54.6)	61.4 (55.8-66.6)	6.0 (-2.0-13.9)
Indiana	35.8 (30.4-41.6)	41.9 (35.8-48.3)	48.4 (42.1-54.8)	45.2 (38.9-51.7)	3.6 (-3.1-10.3)
Michigan	47.6 (41.1-54.2)	48.7 (42.0-55.4)	59.8 (53.7-65.6)	61.3 (54.2-67.9)	5.3 (-0.9-11.5)
Minnesota	40.2 (34.2-46.5)	55.2 (48.2-62.1)	61.2 (54.9-67.1)	59.1 (53.0-65.0)	6.3 (-5.0-17.6)
Ohio	40.4 (34.2-46.9)	48.6 (42.5-54.8)	52.2 (45.4-58.8)	56.2 (49.5-62.8)	5.1 (1.7-8.5)
Wisconsin	45.2 (38.8-51.8)	55.0 (48.2-61.6)	53.3 (47.3-59.2)	61.9 (55.5-67.9)	4.8 (-1.8-11.5)
Region VI	44.4 (40.8-48.0)	45.4 (42.0-48.9)	52.1 (49.5-54.8)	52.0 (49.3-54.8)	2.9 (-1.3-7.1)
Arkansas	30.7 (24.9-37.1)	44.7 (38.4-51.1)	53.6 (47.5-59.5)	54.4 (48.1-60.5)	8.1 (-1.0-17.1)
Louisiana	43.1 (36.5-49.8)	48.9 (42.3-55.5)	54.8 (48.9-60.6)	60.5 (54.4-66.3)	5.8 (5.7-5.9)
New Mexico	49.0 (42.8-55.2)	50.7 (44.3-57.2)	60.4 (54.5-65.9)	60.5 (54.4-66.3)	4.4 (-1.1-10.0)
Oklahoma	49.9 (44.2-55.6)	54.0 (47.6-60.3)	55.5 (48.8-62.0)	56.9 (49.5-63.9)	2.3 (0.3-4.4)
Texas	44.9 (39.9-50.0)	43.5 (38.7-48.3)	50.6 (47.0-54.1)	49.3 (45.6-53.0)	2.0 (-3.4-7.5)
TX-Bexar County	43.9 (37.6-50.5)	41.7 (35.4-48.3)	48.2 (42.0-54.5)	53.4 (46.7-59.9)	3.5 (-2.4-9.4)
TX-City of Houston	50.9 (43.3-58.4)	60.1 (53.1-66.7)	62.7 (55.5-69.4)	62.6 (53.6-70.9)	3.9 (-3.0-10.8)
TX-Dallas County	NA	NA	NA	45.7 (38.5-53.1)	(-.) [¶]
TX-El Paso County	NA	62.6 (55.1-69.6)	67.9 (62.7-72.6)	79.8 (73.6-84.9)	(-.) [¶]
TX-Rest of State	44.5 (38.8-50.4)	41.4 (35.9-47.1)	48.6 (44.1-53.0)	46.8 (42.0-51.6)	1.5 (-4.6-7.6)
Region VII	37.5 (34.0-41.3)	40.2 (36.7-43.8)	52.3 (48.7-55.9)	55.3 (51.8-58.8)	6.5 (0.9-12.2)
Iowa	43.3 (37.3-49.5)	44.5 (37.8-51.4)	57.2 (51.0-63.1)	60.7 (54.8-66.3)	6.4 (0.4-12.4)
Kansas	32.3 (26.1-39.2)	35.5 (29.4-42.1)	43.2 (37.3-49.3)	51.8 (45.2-58.3)	6.6 (2.7-10.5)
Missouri	33.0 (26.6-40.1)	37.5 (31.3-44.1)	51.8 (44.7-58.8)	51.6 (45.0-58.1)	7.0 (-0.9-14.8)
Nebraska	51.3 (44.9-57.8)	49.3 (42.7-55.9)	60.6 (54.9-66.1)	63.7 (57.2-69.8)	4.9 (-2.4-12.2)
Region VIII	38.1 (34.7-41.6)	47.4 (44.1-50.8)	54.8 (51.4-58.2)	57.4 (53.6-61.0)	6.6 (1.9-11.4)
Colorado	45.5 (39.4-51.8)	51.4 (45.3-57.3)	64.2 (58.2-69.9)	63.5 (56.5-69.9)	6.9 (-1.2-15.0)
Montana	34.4 (28.4-40.9)	44.9 (38.4-51.5)	50.4 (44.6-56.2)	55.3 (48.9-61.5)	6.9 (2.9-10.8)
North Dakota	46.6 (40.0-53.2)	49.0 (42.3-55.7)	66.3 (60.0-72.1)	67.6 (60.9-73.5)	8.0 (-1.5-17.6)
South Dakota	38.6 (32.3-45.2)	47.3 (40.7-54.0)	46.0 (39.8-52.3)	55.9 (49.2-62.3)	5.0 (-1.5-11.6)
Utah	27.2 (21.6-33.5)	43.4 (37.4-49.6)	44.2 (38.0-50.7)	49.7 (43.1-56.2)	7.0 (-2.8-16.7)

Wyoming	34.9 (29.1-41.1)	39.5 (34.1-45.1)	42.2 (35.8-48.9)	43.4 (37.5-49.5)	2.8 (0.5-5.1)
Region IX	57.1 (51.6-62.5)	58.2 (52.8-63.4)	62.0 (56.4-67.2)	70.6 (65.6-75.2)	4.6 (-0.5-9.6)
Arizona	54.1 (47.7-60.3)	49.3 (43.0-55.6)	59.7 (53.9-65.1)	63.1 (56.6-69.2)	3.8 (-5.0-12.5)
California	59.0 (52.1-65.6)	60.5 (53.6-67.0)	62.5 (55.4-69.1)	72.6 (66.1-78.2)	4.5 (-1.7-10.6)
Hawaii	46.0 (39.3-52.8)	58.4 (52.2-64.3)	66.8 (60.9-72.2)	64.8 (58.3-70.8)	6.4 (-4.1-16.9)
Nevada	42.6 (36.3-49.1)	48.7 (42.5-54.9)	57.9 (51.5-64.1)	64.9 (58.5-70.8)	7.6 (5.9-9.3)
Region X	46.1 (42.1-50.2)	54.1 (50.2-58.0)	57.2 (53.6-60.8)	62.6 (58.8-66.3)	5.2 (2.4-8.0)
Alaska	39.5 (33.4-46.0)	43.1 (37.1-49.4)	49.1 (42.9-55.2)	61.1 (55.0-66.9)	7.1 (1.3-13.0)
Idaho	44.4 (37.2-51.9)	45.3 (38.6-52.3)	50.6 (44.2-56.9)	57.2 (50.9-63.3)	4.5 (0.6-8.5)
Oregon	50.7 (44.7-56.7)	50.5 (44.1-56.8)	64.1 (58.1-69.8)	61.7 (55.2-67.9)	4.7 (-4.6-14.0)
Washington	44.8 (38.3-51.5)	59.6 (53.2-65.7)	56.1 (50.2-61.8)	64.8 (58.5-70.6)	5.5 (-4.8-15.8)
Range	(27.2 - 72.9)	(35.5 - 72.4)	(42.2 - 84.2)	(43.4 - 88.9)	(1.4 - 8.1)
Territory					
Guam	45.4 (39.3-51.6)	NA	60.2 (54.5-65.7)	67.4 (62.4-72.1)	7.3 (6.7-8.0)
Puerto Rico	NA	64.9 (56.0-72.9)	72.6 (66.3-78.0)	75.8 (70.2-80.6)	(.-.) [¶]
U.S. Virgin Islands	24.6 (19.6-30.4)	NA	37.9 (32.8-43.2)	41.9 (36.2-47.7)	5.9 (-2.6-14.5)

Abbreviations: CI = confidence interval; HHS = U.S. Department of Health and Human Services; HPV = human papillomavirus; NA = not available (Data was not collected for that survey year).

* HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.

[†] The "Most Current 4 Years Annual Average Increase" was computed by using weighted linear regression for each awardee, with weights inverse proportional to the estimated variance of each estimate. Confidence intervals which did not include zero were considered statistically significant.

[§] 95% confidence intervals were computed using the Wald test. Estimates with 95% CI half-widths >10 might not be reliable.

[¶] Estimates for jurisdictions have been suppressed if data for either 2013 or 2016 are not available or if data are available for fewer than three of the four years.